In recent years, EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, icotinib, afatinib, and osimertinib, have been used as first-line treatment for NSCLC patients with EGFR-activating mutations (Tian et al., 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.